Major trial aims to shield children from malaria with new vaccine
NCT ID NCT04704830
Summary
This large, final-stage trial is testing whether a new vaccine called R21/Matrix-M can safely protect young children in Africa from getting sick with malaria. It involves 4,800 children aged 5-36 months across several African countries. The study compares the malaria vaccine against control vaccines to measure how well it prevents the disease over several years, including with different booster shot schedules.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CCVTM, University of Oxford, Churchill Hospital
Oxford, OX3 7LE, United Kingdom
Conditions
Explore the condition pages connected to this study.